RADIATE: More treatment options for patients with an inadequate response to tumor necrosis factor antagonists

Nature Clinical Practice Rheumatology

Volumn 5, Issue 2, 2009, Pages 66-67

  Choy, Ernest ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFECTION; JOINT INJURY; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; MONOTHERAPY; NEUTROPENIA; NOTE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION;

EID: 59849098178     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0984     Document Type: Note

References (9)

1. Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 56: 13-20
2. Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial. Lancet 371: 987-997
3. Genovese MC et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968-2980
4. Emery P et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523
5. Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 1162-1167
6. Finckh A et al. (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56: 1417-1423
7. Smolen J et al. (2008) Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]. Ann Rheum Dis 67 (suppl 2): 50
8. Cohen SB et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806
9. Genovese MC et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114-1123